The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics.

Autor:	Zeinalzadeh E; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Valerievich Yumashev A; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia., Rahman HS; College of Medicine, University of Sulaimani, Sulaimaniyah, Iraq.; Department of Medical Laboratory Sciences, Komar University of Science and Technology, Sulaimaniyah, Iraq., Marofi F; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran., Shomali N; Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Kafil HS; German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany., Solali S; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Sajjadi-Dokht M; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Vakili-Samiani S; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Jarahian M; German Cancer Research Center, Toxicology and Chemotherapy Unit (G401), Heidelberg, Germany., Hagh MF; Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Jazyk:	angličtina
Zdroj:	Frontiers in genetics [Front Genet] 2021 Dec 21; Vol. 12, pp. 703883. Date of Electronic Publication: 2021 Dec 21 (Print Publication: 2021).
DOI:	10.3389/fgene.2021.703883
Abstrakt:	The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway has been known to be involved in cell growth, cellular differentiation processes development, immune cell survival, and hematopoietic system development. As an important member of the STAT family, STAT3 participates as a major regulator of cellular development and differentiation-associated genes. Prolonged and persistent STAT3 activation has been reported to be associated with tumor cell survival, proliferation, and invasion. Therefore, the JAK-STAT pathway can be a potential target for drug development to treat human cancers, e.g., hematological malignancies. Although STAT3 upregulation has been reported in hematopoietic cancers, protein-level STAT3 mutations have also been reported in invasive leukemias/lymphomas. The principal role of STAT3 in tumor cell growth clarifies the importance of approaches that downregulate this molecule. Epigenetic modifications are a major regulatory mechanism controlling the activity and function of STAT3. So far, several compounds have been developed to target epigenetic regulatory enzymes in blood malignancies. Here, we discuss the current knowledge about STAT3 abnormalities and carcinogenic functions in hematopoietic cancers, novel STAT3 inhibitors, the role of epigenetic mechanisms in STAT3 regulation, and targeted therapies, by focusing on STAT3-related epigenetic modifications. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Zeinalzadeh, Valerievich Yumashev, Rahman, Marofi, Shomali, Kafil, Solali, Sajjadi-Dokht, Vakili-Samiani, Jarahian and Hagh.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu